Daiichi Sankyo’s Enhertu Submitted for Priority Review in China for HER2-Positive Breast Cancer
On August 22, 2025, Daiichi Sankyo (TYO: 4568) submitted a marketing authorization application for Enhertu...
DATROWAY Approved in China for HR-Positive, HER2-Negative Breast Cancer
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) announced that DATROWAY has been approved...
Yantai Dongcheng’s 225Ac-LNC1011 Injection Gains FDA Approval for Prostate Cancer Trial
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675), a China-based company, announced that its 225Ac-LNC1011...
Ocumension’s OT-301 Meets Primary Endpoint in Denali Phase III Trial
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) , a China-based pharmaceutical company, announced on August 21,...
Zhejiang Medicine Receives NMPA Approval for Phase 1 Trial of XC2309 Injection
Zhejiang Medicine Co., Ltd. (SHA: 600216), a China-based pharmaceutical company, announced that it has received...
Shanghai Bao Pharma Files for Hong Kong IPO, Aiming to Boost Biologics Development
Shanghai Bao Pharmaceuticals Co. Ltd., a company leveraging synthetic biology to develop recombinant biologics, submitted...
Zhongsheng Pharma’s Onradivir Granted Drug Registration in Macau
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that its onradivir tablets have received a...
Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners
Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the...
Hengrui Pharmaceuticals Reports 15.88% Revenue Growth in 2025 Semi-Annual Results
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) has released its 2025 semi-annual report, highlighting...
China’s NMPA Resumes Import of Vasudha’s Loratadine API After Rectifications
China’s National Medical Products Administration (NMPA) announced on August 20, 2025, that it had resumed...
Jazz Pharmaceuticals Secures Global Rights to Saniona’s Epilepsy Drug SAN2355
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Saniona (STO: SANION) announced today that they have entered...
Kite Pharma Acquires Interius BioTherapeutics for $350 Million to Boost CAR Therapy Platform
On August 22, 2025, Kite Pharma, Inc., a subsidiary of Gilead Sciences (NASDAQ: GILD), announced...
Ionis Pharmaceuticals’ DAWNZERA Approved by FDA for HAE Prevention
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced on August 22, 2025, that the U.S. Food and...
InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors
China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has announced...
Lifetech Scientific’s PDA Occluder Gains NMPA Innovative Device Review Status
On August 22, 2025, China-based Lifetech Scientific Corporation (HKG: 1302) announced that its nitinol patent...
Bio-Thera Inks EUR 136m Deal with STADA for BAT1806 Commercialization
On August 21, 2025, Bio-Thera Solutions, Ltd. (SHA: 688177) announced a license and commercialization agreement...
3D Medicines and CATUG Biotech Forge Strategic Alliance in mRNA-LNP Innovation
China-based 3D Medicines (HKG: 1244) has entered into a strategic cooperation framework agreement with CATUG Biotechnology....
Bio-Thera Adjusts BAT3306 Clinical Study to Meet Regulatory Standards
On August 21, 2025, China-based Bio-Thera Solutions, Ltd. (SHA: 688177) announced a strategic adjustment to...
Novartis’ Atrasentan Approved in China for IgAN Proteinuria Reduction
Switzerland-based Novartis (NYSE: NVS) has received approval from China’s National Medical Products Administration (NMPA) for...
Suzhou Zelgen’s ZG005 and Gecacitinib Win NMPA Approval for Advanced Solid Tumors
On August 21, 2025, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266), a China-based company, announced...